10-K: GoodRx Navigates Evolving Healthcare Landscape, Reports Modest Growth

GoodRx Holdings, Inc. reported a 1% revenue increase in 2025, driven by strong pharma direct growth despite challenges in prescription transactions and a changing retail pharmacy landscape.

Summary

• Total revenue increased 1% year-over-year to $796.9 million in 2025, up from $792.3 million in 2024.
• Net income rose to $30.4 million (3.8% margin) in 2025, compared to $16.4 million (2.1% margin) in 2024.
• Adjusted EBITDA increased to $270.5 million (33.9% margin) in 2025, from $260.2 million (32.8% margin) in 2024.
• Prescription transactions revenue decreased 6% to $544.0 million in 2025, primarily due to a 14% decrease in Monthly Active Consumers.
• Monthly Active Consumers averaged 5.3 million in Q4 2025, down from 6.6 million in Q4 2024.
• Subscription revenue decreased 3% to $83.8 million in 2025, with subscription plans declining to 674,000 as of December 31, 2025, from 684,000 a year prior.
• Pharma direct revenue surged 41% to $151.4 million in 2025, driven by organic growth and expanded market penetration.
• Acquired ScriptDrop, a prescription delivery technology platform, for $13.4 million in cash on October 16, 2025.
• Acquired VCRx, a prescription savings business, for $30.0 million in cash on January 13, 2025.
• An estimated probable loss of $30.5 million was recognized relating to an ongoing consumer privacy class-action lawsuit.
• The company repurchased 48.853 million shares of Class A common stock for $217.437 million in 2025.
• Cash and cash equivalents stood at $261.8 million as of December 31, 2025, with $80.2 million available under the revolving credit facility.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a challenging period for GoodRx, with core prescription transaction and user metrics declining, offset by strong growth in the smaller pharma direct segment. The strategic shift and acquisitions are positive long-term moves, but near-term headwinds are significant.

Positives

• Overall revenue increased by 1% year-over-year, demonstrating continued top-line growth.
• Net income and Adjusted EBITDA margins improved significantly, indicating enhanced profitability and operational efficiency.
• Pharma direct revenue grew substantially by 41%, highlighting successful diversification and market penetration in a key strategic area.
• Strategic acquisitions of ScriptDrop and VCRx are expected to expand business capabilities, enhance prescription delivery solutions, and improve consumer reach.
• Launch of new condition-specific subscription programs (erectile dysfunction, weight management, hair loss) and RxSmartSaver+ in 2025 diversifies offerings and targets higher lifetime value consumers.
• Collaboration with a pharmaceutical manufacturer to offer significantly lower cash prices for in-demand GLP-1 medications addresses a high-growth market segment.
• GoodRx is a key integration partner for pharma manufacturers on the new government-sponsored TrumpRx.gov platform, positioning the company within emerging federal initiatives.
• Maintained strong liquidity with $261.8 million in cash and cash equivalents and $80.2 million available under the revolving credit facility as of December 31, 2025.
• Management concluded that internal control over financial reporting was effective as of December 31, 2025.

Negatives

• Prescription transactions revenue, the company's primary revenue source, decreased by 6% year-over-year.
• Monthly Active Consumers experienced a significant 14% decrease, indicating a contraction in the core user base.
• Subscription revenue declined by 3%, and the total number of subscription plans decreased, suggesting challenges in this segment.
• The changing U.S. retail pharmacy landscape, including Rite Aid's bankruptcy and store closures, adversely impacted revenues, with an estimated combined total impact of $35.0 million to $40.0 million in 2025.
• A material volume reduction occurred in one of the integrated savings programs in the first half of 2025.
• An estimated probable loss of $30.5 million was recognized related to an ongoing consumer privacy class-action lawsuit, with preliminary settlement approval denied twice by the court.
• Interest income decreased by 53% due to lower average cash equivalents and interest rates.
• Cost of revenue increased by 19%, primarily driven by higher processing fees.
• Income tax expense increased by 73% due to higher income before taxes and lower 2025 tax benefits.

Risks

• Limited operating history and evolving business make future prospects difficult to evaluate and historical growth rates may not be sustainable.
• Inability to achieve broad market education and change consumer purchasing habits regarding prescription savings.
• Failure to attract, acquire, and retain consumers cost-effectively, or to maintain the scale necessary for operational efficiency.
• Significant reliance on the prescription transactions offering, with potential for decline due to competition, pricing fluctuations, and retail pharmacy closures.
• Business is subject to changes in medication pricing and pricing structures negotiated by industry participants (pharma manufacturers, wholesalers, PBMs, pharmacies).
• Lack of control over the categories and types of prescriptions for which savings or discounted prices can be offered.
• Reliance on a limited number of industry participants, including PBMs and national pharmacy chains, poses risks if relationships deteriorate or consolidation occurs.
• Operating in a highly competitive industry and potential failure to effectively differentiate offerings from competitors.
• Overestimation of the total addressable market (TAM) could limit future growth opportunities.
• Inaccuracies in internally calculated operational metrics (e.g., Monthly Active Consumers, Monthly Visitors, subscribers) may harm reputation and affect business.
• Inability to successfully respond to changes in the market for prescription pricing and maintain/expand the use of GoodRx codes.
• Inability to maintain a positive perception regarding the platform or enhance the brand, potentially leading to loss of consumers and partners.
• Failure to maintain effective internal control over financial reporting could adversely affect investor confidence and stock value.
• Use of social media, emails, and text messages may adversely impact reputation, subject the company to fines, or be an ineffective marketing source.
• Dependence on information technology systems and those of third-party vendors, with risks of failures, disruptions, security breaches, or data loss.
• Evolving government regulation of the internet and e-commerce, and potential non-compliance, could harm business and results.
• Risk of litigation resulting from unauthorized text messages sent in violation of the Telephone Consumer Protection Act (TCPA).
• Actual or perceived failures to comply with applicable data protection, privacy, security, advertising, and consumer protection laws, regulations, and standards.
• Inability to realize expected benefits from restructuring and cost reduction efforts, potentially leading to unintended consequences and adverse business impacts.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be limited by tax laws (e.g., Section 382 of the Code).
• Reliance on the performance of management and highly skilled personnel; inability to attract, develop, motivate, and retain well-qualified employees.
• Impact of pandemics, epidemics, or outbreaks of infectious diseases on business operations and consumer behavior.
• General economic factors, natural disasters, or other unexpected events may adversely affect business and financial performance.
• Risks associated with growing the business through acquisitions, investments, or strategic alliances, including integration challenges and unanticipated costs.
• Restrictions in debt arrangements could adversely affect operating flexibility, and failure to comply could result in debt acceleration.
• Dependence on network and mobile infrastructure and ability to maintain/scale technology; interruptions or delays could lead to loss of consumers.
• Reliance on third-party platforms (e.g., Apple App Store, Google Play Store) and SaaS technologies, with risks of service unavailability or changes in terms.
• Changes in consumer sentiment or laws/regulations regarding the use of cookies and other tracking technologies could impact revenue generation and data collection.
• Subject to climate-related risks, including meteorological phenomena and increased regulations, potentially leading to higher costs and operational disruptions.
• ESG initiatives could increase costs, harm reputation, and adversely impact financial results due to evolving stakeholder expectations and regulatory requirements.
• Inability to establish, maintain, protect, and enforce intellectual property and proprietary rights, or prevent unauthorized use by third parties.
• Risk of being sued by third parties for infringement, misappropriation, dilution, or other violations of their intellectual property rights.
• Inability to protect the confidentiality of trade secrets, which could harm business and competitive position.
• Issued patents covering offerings could be found invalid or unenforceable if challenged.
• Utilization of open-source software may pose risks to proprietary software and solutions.
• Failure to comply with obligations under license or technology agreements with third parties could lead to damages or loss of critical license rights.
• Impact of healthcare reform legislation and other proposed or future changes (e.g., Inflation Reduction Act, One Big Beautiful Bill Act, TrumpRx.gov, GLP-1 regulations) on the healthcare industry and GoodRx's business.
• Organizational structure risks, including agreements and relationships with significant stockholders and the dual-class structure, may adversely affect the trading market for Class A common stock.
• Volatility in stock price due to numerous factors beyond the company's control, potentially resulting in substantial losses for investors.
• Inability to accurately forecast revenue and appropriately plan expenses in the future.

Future Outlook

GoodRx expects pharma direct revenue to continue growing as a percentage of total revenue in the near to medium term. The company anticipates a near-term impact on prescription transactions unit economics and revenue in 2026 due to increased investment in pharma direct and subscription offerings, believing this transition enhances long-term growth prospects and sustainable value creation. The closure of Rite Aid stores is also expected to adversely impact revenues in 2026.

Management Comments

• Our mission is to help Americans save time and money when filling their medications.
• With the introduction of these federal initiatives, including the renewed focus on Most-Favored-Nation pricing, the market is shifting decisively toward greater transparency and direct-to-consumer access. For us, this evolution is both an opportunity and a clear validation of our mission.
• While our prescription transactions offering remains foundational, given the evolving dynamics of prescription access and pharmacy economics, including the growing relevance of self-pay and direct-to-consumer distribution models, we are continuing to position our pharma direct offering as a key driver of growth.
• As we increase investment in our pharma direct as well as subscription offerings, we expect near-term impact on our prescription transactions unit economics and revenue in 2026.
• Accordingly, while this transition may impact near-term financial performance, we believe it enhances our long-term growth prospect and ability to create sustainable value.

Industry Context

StockSavvy.ai notes that GoodRx is navigating a complex and rapidly evolving U.S. healthcare landscape marked by increasing consumer cost burden, government initiatives like TrumpRx.gov promoting direct-to-consumer discounts, and significant retail pharmacy consolidation and closures (e.g., Rite Aid, Walgreens). The company's strategic shift towards pharma direct and condition-specific subscriptions aligns with broader industry trends of digital health adoption and personalized care, while also responding to challenges in traditional prescription transaction models. The increased scrutiny on PBMs by the FTC and Congress, along with new legislation like the IRA and OBBBA, creates both opportunities for transparency and risks of regulatory changes impacting pricing structures.

Comparison to Industry Standards

• The U.S. healthcare market is estimated at approximately $5.3 trillion, with GoodRx's estimated total addressable market for its primary solutions between $600 billion and $710 billion, including a $581 billion to $691 billion prescription opportunity and a $19 billion pharma direct opportunity. This indicates a significant untapped market for GoodRx's services, suggesting substantial growth potential relative to its current market share.
• The company's 1% revenue growth and 14% decline in Monthly Active Consumers contrast with some segments of the broader digital health sector that may be experiencing faster user growth, but also reflects the specific challenges and maturity of the prescription discount market.
• The 41% growth in pharma direct revenue suggests strong performance in a segment that is increasingly critical for pharmaceutical manufacturers seeking direct patient engagement and affordability solutions, potentially outperforming traditional pharmaceutical marketing channels and demonstrating effective adaptation to evolving industry needs.
• The legal challenges and heightened regulatory scrutiny faced by Pharmacy Benefit Managers (PBMs), as highlighted by the FTC's administrative complaint against the three largest PBMs, indicate a turbulent environment for key industry intermediaries. GoodRx's ability to maintain and adapt its relationships with these PBMs is crucial for its business model, especially as some PBMs begin offering competing discount cards.

Management Changes

Corporate Governance

Legal Proceedings

• Consumer privacy class action (NDCA Class Action Matter): Consolidated lawsuits alleging inadequate consumer privacy protection and communication of consumer information to third parties. Plaintiffs seek monetary damages and injunctive relief. A proposed settlement of $25.0 million was denied preliminary approval by the court on June 12, 2025, with leave to refile. An amended settlement agreement filed on November 19, 2025, was also denied preliminary approval on January 16, 2026, requesting additional information.
• Consumer privacy class action (SDFL Class Action Matter): Similar claims, with a proposed settlement of $13.0 million that received preliminary approval on October 31, 2023, but was later voluntarily dismissed with prejudice on December 4, 2024.
• Consumer state litigation (Mullens Foundation, Arkansas): Lawsuit alleging violation of an Arkansas statute related to health-related discount cards not expressly stating discounts are not insurance and cancellation rights. A motion to dismiss was denied on December 2, 2024, and the Arkansas Attorney General moved to intervene on May 9, 2025.
• Consumer state litigation (State of Arkansas, ex rel. Tim Griffin): Filed suit alleging similar violations as Mullens Foundation plus Arkansas Deceptive Trade Practices Act. A Consent Judgment was entered on September 25, 2025, releasing GoodRx from certain claims for cards distributed from January 1, 2022, until the agreement's effective date, with immaterial monetary relief.
• Consumer state litigation (Minnesota Teamsters Service Bureau): Lawsuit alleging violation of a Minnesota statute related to health-related discount cards. A motion to dismiss was denied on December 17, 2024. On February 5, 2026, the court dismissed plaintiff's claims as time-barred.

Related Party Transactions

• Repurchased 20.0 million shares of Class A common stock from Francisco Partners, Idea Men, LLC, and Spectrum (related parties) in March 2025 for an aggregate of $84.9 million.
• Repurchased 20.9 million shares of Class A common stock from Francisco Partners and Spectrum (related parties) in March 2024 for an aggregate of $151.4 million.
• Repurchased 12.0 million shares of Class A common stock from Spectrum (a related party) in November 2023 for an aggregate of $65.9 million.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to declining core metrics, ongoing legal proceedings, and market uncertainties. Share repurchase programs aim to return value, but the dual-class structure and significant stockholder control limit the influence of other shareholders.
• Consumers: Continued access to discounted prescription prices, new condition-specific subscription programs, and GLP-1 medication savings. However, retail pharmacy closures and changes in integrated savings programs may impact access and savings for some. Privacy concerns and class-action lawsuits could erode trust.
• Employees: Restructuring and cost reduction efforts, including workforce reductions, could impact morale and institutional knowledge. New CEO and CFO appointments signal leadership transition and strategic re-alignment.
• Pharmacies: GoodRx aims to deepen relationships, drive traffic, and improve margins for partner pharmacies. However, PBM-pharmacy renegotiations and retail pharmacy closures create instability and challenges for the pharmacy network.
• PBMs: GoodRx provides a platform to drive incremental volume to PBM cash networks. Increased competition from other third-party discount cards on PBM platforms and heightened regulatory scrutiny on PBMs could affect relationships and revenue streams.
• Pharma Manufacturers: GoodRx offers an attractive platform for advertising and integrating affordability solutions, leading to increased medication awareness, access, and adherence. Participation in TrumpRx.gov represents a new channel for direct-to-consumer engagement.

Next Steps

• Continue to attract new consumers and increase awareness of the platform and its offerings.
• Facilitate existing GoodRx consumers' adoption of multiple offerings to increase consumer lifetime value and margins.
• Deepen relationships with retail pharmacies to enhance pricing competitiveness, improve consumer experience, and drive increased prescription volume.
• Invest in product offerings, particularly expanding the pharma direct and subscription offerings, and introducing new integrated technology solutions.
• Pursue strategic partnerships and acquisitions to strengthen market position and enhance capabilities.
• Focus on delivering consistent and efficient growth by reprioritizing investments.
• Monitor and adapt to the evolving regulatory landscape, including new AI laws and drug pricing policies (e.g., TrumpRx.gov, Globe and Guard regulations).
• Continue to vigorously defend against ongoing legal proceedings related to consumer privacy and discount card statutes.

Key Dates

Recommendation

GoodRx is undergoing a significant strategic transition, shifting focus towards higher-margin pharma direct and subscription offerings while its foundational prescription transactions business faces headwinds from pharmacy closures and declining Monthly Active Consumers. While the growth in pharma direct is a positive sign of diversification, the overall revenue growth is modest, and core user metrics are declining. The ongoing legal challenges and regulatory uncertainties add to the risk profile. The company's strong cash position and share repurchase program provide some stability, but the near-term financial performance is expected to be impacted by this transition. A 'hold' recommendation is appropriate as investors await clearer signs of successful execution of the new strategy and stabilization of core metrics amidst a dynamic healthcare landscape.

Keywords

GoodRx, GDRX, SEC Filing, 10-K, Healthcare Technology, Prescription Savings, Pharma Direct, Telehealth, Digital Healthcare, Financial Results, Risk Factors, Corporate Governance, Acquisitions, Stock Repurchase, Privacy Lawsuit, GLP-1, TrumpRx.gov, PBMs, Pharmacy Benefit Managers, Retail Pharmacy, Subscription Services